PTC Therapeutics, Inc.
PTC Therapeutics develops medicines for rare disorders globally. Products include Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi for conditions like Duchenne muscular dystrophy, SMA, and AADC deficiency. Pipeline products include Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease, and vatiquinone/utreloxastat for Friedreich ataxia/Amyotrophic lateral sclerosis. The company distributes through third-party distributors. It has collaborations with various organizations.
Overview
Strengths
- With an appreciation Potential of 37.89%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (7.57) is lower than the sector mean (91.15).
- The company has high returns. ROIC (29.76%) is higher than the sector mean (6.02%).
- EV/EBITDA (7.73) is lower than the sector mean (85.60).
- EV/EBIT (7.99) is lower than the sector mean.
- Price to free cash flow (12.57) is lower than the sector mean.
- Strong EBITDA Margin of 50.69%.
Weaknesses
- Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
- The company has high debt. Net Debt to EBITDA Ratio (1.84) is higher than the sector mean.
Key Financial Data